期刊文献+

绝经后骨质疏松症的治疗新进展 被引量:37

Therapeutic Progress of Postmenopausal Osteoporosis
在线阅读 下载PDF
导出
摘要 当今随着绝经后妇女人数增加,与绝经相关的骨质疏松症日益受到社会广泛关注,其预防、治疗已是当前许多国家重要保健课题之一,近年其治疗进展迅速,现就绝经后骨质疏松症的药物治疗、非药物治疗进行综述。 With the inreasing number of Postmenopausal nowdays, Osteoporesis related to menostasia is attracting more and more attention from social, whose prevention and cure is one of important topic in heath care of many countries. Its therapeutic progress is going forward rapidly. This article reviews drug therapy, non-drug therapy of this disease.
作者 吕靖 马彩玲
出处 《医学综述》 2007年第1期62-63,共2页 Medical Recapitulate
关键词 绝经后 骨质疏松症 治疗 中医药疗法 Postmenopause Osteoporosis Treatment Medication with chinese traditional medicine
  • 相关文献

参考文献14

  • 1邱明才.骨质疏松研究的现状与展望[J].中华医学杂志,2001,81(14):833-835. 被引量:102
  • 2Lane JM,Russell L,Khan SN.Osteoporosis[J].Clin Orthop Relat Res,2000,372(3):139-150.
  • 3丁立忠,傅鹰.性激素补充疗法指南类文献的系统性综述[J].药物流行病学杂志,2003,12(5):264-271. 被引量:19
  • 4Nelson HD,Humphrey LL,Nygren P,et al.Postmenopausal hormone replancement theraphy:Scientific review[J].JAMA,2002,288 (7):872-881.
  • 5Gradisher WJ,Jordan VC.clinical potential of new antiestrogens[J].J Clin Oncol,1997,15(2):840-852.
  • 6Draper MW,Flowers DE,Huster WJ,et al.A controlled trial of raloxifene(LY139481)HCI:impact on bone turnover and serum lipid profile in healthy postmenopausal women[J].J Bone Miner Res,1996,11 (6):835-842.
  • 7Drake FH,Dodds RA,James IE,et al.Cathepsin K,but not cathepsins B,L,or S,is abundantly expressed in human osteoclasts[J].J Biol Chem,1996,271 (21):12511-12516.
  • 8Ramaza T,Goto T,Kamiya T,et al.Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur[J].Bone,1998,23(6):499-509.
  • 9孟迅吾,李梅.甲状旁腺素防治原发性骨质疏松症的研究进展[J].国外医学(内分泌学分册),2003,23(2):106-107. 被引量:9
  • 10Seeman E,Delmas PD.Reconstructing the skeleton with intermittent parathyroid hormone[J].Trends Endocrinol Metab,2001,12 (7):281 -283.

二级参考文献35

  • 1Boukes FS Groeneveld assendelft WJ.Summary or the DCGP practice guiddine"the menopause"[J].Ned Tijdschr Geneeskd,2002,146:1317-1320.
  • 2Siegemann-Danieli N Ron I Kaufman B et al.HRT in breast cancer survivors: ISCADR polipy letter[J].Harefuah,2002,141(11):994-994.
  • 3Writing Group for the WHI Investigatiors. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288: 321-333.
  • 4Mosca L, Collins P, Herington DM, et al. HRT and Cardiovaseular disease. A statement for healtheare professeinals from the AHA. Circulation, 2001,104:499-503.
  • 5ACC/AHA. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-Stmamary article. Circulation ,2003,107:149-158.
  • 6Stephertson J. FDA order estrogen safety warnings. Agency offers guidance for HRT use. JAMA, 2003,289:537-538.
  • 7(HC)Pritehard KI, Khan H, Levine M, et al. Clinical practice guidelines for the care and treatment of breeast cancer: 14. The role of HRT in women with a previous diagnosis of breat cancer. CMAJ, 2002, 166(8): 1017-1022(2002-4).
  • 8NAMS. Amended report from the NAMS Advisory Panel on HRT. Menopause, 2003,10(1) : 6-12.
  • 9NAMS. Role of progestogen in hormone therapy for postmenopausal women: Position statement of NAMS.Menopause, 2003,10(2) : 113.
  • 10Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAI, 2002,167( 10 suppl) : s1-s18.

共引文献139

同被引文献398

引证文献37

二级引证文献253

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部